EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries

Jui Vyas iD, Jeffrey R Johns iD, Faraz M Ali iD, Ravinder K Singh, John R Ingram iD, Sam Salek iD, Andrew Y Finlay iD

British Journal of Dermatology · 16.02.2024 · 190 (3) · 315-339

DOI: 10.1093/bjd/ljad079 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift British Journal of Dermatology, online erschienen am 27.03.2023. Verfasst von Jui Vyas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medical Education. Hauptthemen laut MEDLINE: Quality of Life, Randomized Controlled Trials as Topic, Patient Reported Outcome Measures, Skin Diseases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 491 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Division of Infection and Immunity, School of Medicine, Cardiff University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Over 29 years of clinical application, the Dermatology Life Quality Index (DLQI) has remained the most used patient-reported outcome (PRO) in dermatology due to its robustness, simplicity and ease of use.

Objectives

To generate further evidence of the DLQI's utility in randomized controlled trials (RCTs) and to cover all diseases and interventions.

Methods

The methodology followed PRISMA guidelines and included seven bibliographical databases, searching articles published from 1 January 1994 until 16 November 2021. Articles were reviewed independently by two assessors, and an adjudicator resolved any opinion differences.

Results

Of 3220 screened publications, 454 articles meeting the eligibility criteria for inclusion, describing research on 198 190 patients, were analysed. DLQI scores were primary endpoints in 24 (5.3%) of studies. Most studies were of psoriasis (54.1%), although 69 different diseases were studied. Most study drugs were systemic (85.1%), with biologics comprising 55.9% of all pharmacological interventions. Topical treatments comprised 17.0% of total pharmacological interventions. Nonpharmacological interventions, mainly laser therapy and ultraviolet radiation treatment, comprised 12.2% of the total number of interventions. The majority of studies (63.7%) were multicentric, with trials conducted in at least 42 different countries; 40.2% were conducted in multiple countries. The minimal clinically importance difference (MCID) was reported in the analysis of 15.0% of studies, but only 1.3% considered full score meaning banding of the DLQI. Forty-seven (10.4%) of the studies investigated statistical correlation of the DLQI with clinical severity assessment or other PRO/quality of life tools; and 61–86% of studies had within-group scores differences greater than the MCID in ‘active treatment arms’. The Jadad risk-of-bias scale showed that bias was generally low, as 91.8% of the studies had Jadad scores of ≥ 3; only 0.4% of studies showed a high risk of bias from randomization. Thirteen per cent had a high risk of bias from blinding and 10.1% had a high risk of bias from unknown outcomes of all participants in the studies. In 18.5% of the studies the authors declared that they followed an intention-to-treat protocol; imputation for missing DLQI data was used in 34.4% of studies.

Conclusions

This systematic review provides a wealth of evidence of the use of the DLQI in clinical trials to inform researchers’ and ­clinicians’ decisions for its further use. Recommendations are also made for improving the reporting of data from future RCTs using the DLQI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeRandomized Controlled Trials as TopicPatient Reported Outcome MeasuresSkin DiseasesHumansDermatologic AgentsDermatologySeverity of Illness Index

Substanzen

Dermatologic Agents

Autor:innen und Institutionen

  • Centre for Medical Education.
  • Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
  • School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.

ORCID-Profile: Jui Vyas, Jeffrey R Johns, Faraz M Ali, John R Ingram, Sam Salek, Andrew Y Finlay

Förderung

  • Division of Infection and Immunity
  • School of Medicine
  • Cardiff University

Zitieren

APA

Vyas, J., Johns, J. R., Ali, F. M., Singh, R. K., Ingram, J. R., Salek, S., & Finlay, A. Y. (2024). A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries. British Journal of Dermatology, 190(3), 315-339. https://doi.org/10.1093/bjd/ljad079

Vancouver

Vyas J, Johns JR, Ali FM, Singh RK, Ingram JR, Salek S, et al. A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries. British Journal of Dermatology. 2024;190(3):315-339. doi:10.1093/bjd/ljad079

BibTeX
@article{Vyas2024,
  author = {Vyas, Jui and Johns, Jeffrey R and Ali, Faraz M and Singh, Ravinder K and Ingram, John R and Salek, Sam and Finlay, Andrew Y},
  title = {A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries},
  journal = {British Journal of Dermatology},
  year = {2024},
  volume = {190},
  number = {3},
  pages = {315--339},
  doi = {10.1093/bjd/ljad079}
}
Kostenlos starten →